{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:13:21Z","timestamp":1781090001183,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of the study is to investigate the difference in 1-year late lumen loss (LLL) between the high- (IN.PACT Admiral) and low-dose (Lutonix) paclitaxel-coated balloon (PCB). Although a recent randomized clinical trial demonstrated no difference in efficacy endpoint between high- and low-dose PCB, it remains unclear whether high-dose PCB was superior to low-dose PCB in actual clinical practice. We enrolled 64 patients with 67 de novo femoropopliteal lesions who underwent PCB angioplasty at Kokura Memorial Hospital from May 2014 to March 2020 and subsequent follow-up angiography after 1\u00a0year. The primary endpoint was 1-year LLL, whereas the secondary endpoints were binary restenosis and clinically driven target lesion revascularization (CD-TLR) after 1\u00a0year. The high- and low-dose PCB groups had 45 and 22 lesions, respectively. Although the low-dose PCB group had higher rates of coronary artery disease, hemodialysis, and chronic limb-threatening ischemia than the high-dose PCB group, the latter had a longer lesion length and more lesions with a TASC classification C or D than the former. The high-dose PCB group had a significantly lower LLL than the low-dose PCB group (0.40\u2009\u00b1\u20091.05 vs. 1.19\u2009\u00b1\u20091.03\u00a0mm; <jats:italic>P<\/jats:italic>\u2009=\u20090.003, respectively). Moreover, the high-dose PCB group had significantly lower rates of binary restenosis at 1\u00a0year than the low-dose PCB group (22.2% vs. 50.0%; <jats:italic>P<\/jats:italic>\u2009=\u20090.02, respectively). Moreover, negative LLL was only observed in the high-dose PCB group (33.3% vs. 0%, <jats:italic>P<\/jats:italic>\u2009=\u20090.005). The high-dose PCB group had a significantly lower LLL than the low-dose PCB group.<\/jats:p>","DOI":"10.1007\/s00380-024-02370-0","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T11:02:39Z","timestamp":1708081359000},"page":"582-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Difference in one-year late lumen loss between high- and low-dose paclitaxel-coated balloons for femoropopliteal disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Kenji","family":"Kodama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tomoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-9314","authenticated-orcid":false,"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"2370_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR (2015) Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 131:495\u2013502","journal-title":"Circulation"},{"key":"2370_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1406235","volume":"373","author":"K Rosenfield","year":"2015","unstructured":"Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, M\u00fcller-H\u00fclsbeck S, Nehler MR, Benenati JF, Scheinert D (2015) Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 373:145\u2013153","journal-title":"N Engl J Med"},{"key":"2370_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa0706356","volume":"358","author":"G Tepe","year":"2008","unstructured":"Tepe G, Zeller T, Albrecht T, Heller S, Schwarzw\u00e4lder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358:689\u2013699","journal-title":"N Engl J Med"},{"key":"2370_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jcin.2018.01.276","volume":"11","author":"S Steiner","year":"2018","unstructured":"Steiner S, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Str\u00f6bel A, Schult I, Scheinert D (2018) 12-Month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv 11:934\u2013941","journal-title":"JACC Cardiovasc Interv"},{"key":"2370_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/1526602817745565","volume":"25","author":"O Iida","year":"2018","unstructured":"Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, Ookubo H, Yokoi H (2018) Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther 25:109\u2013117","journal-title":"J Endovasc Ther"},{"key":"2370_CR6","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00380-021-01970-4","volume":"37","author":"T Shimada","year":"2022","unstructured":"Shimada T, Shima Y, Takahashi K, Miura K, Takamatsu M, Ikuta A, Habara S, Tanaka H, Goto T, Izumiya Y, Kadota K (2022) Delayed stenosis regression after drug-coated balloon angioplasty for femoropopliteal artery lesions. Heart Vessels 37:730\u2013737","journal-title":"Heart Vessels"},{"key":"2370_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/1526602815626557","volume":"23","author":"K Katsanos","year":"2016","unstructured":"Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D (2016) Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther 23:356\u2013370","journal-title":"J Endovasc Ther"},{"key":"2370_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.jcin.2015.03.020","volume":"8","author":"CA Gongora","year":"2015","unstructured":"Gongora CA, Shibuya M, Wessler JD, McGregor J, Tellez A, Cheng Y, Conditt GB, Kaluza GL, Granada JF (2015) Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv 8:1115\u20131123","journal-title":"JACC Cardiovasc Interv"},{"key":"2370_CR9","doi-asserted-by":"publisher","first-page":"e560","DOI":"10.4244\/EIJ-D-18-00550","volume":"15","author":"S Cassese","year":"2019","unstructured":"Cassese S, Ndrepepa G, Fusaro M, Kufner S, Xhepa E (2019) Paclitaxel density and clinical efficacy of drug-coated balloon angioplasty for femoropopliteal artery disease: meta-analysis and adjusted indirect comparison of 20 randomised trials. EuroIntervention 15:e560\u2013e562","journal-title":"EuroIntervention"},{"key":"2370_CR10","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehaa049","volume":"41","author":"S Steiner","year":"2020","unstructured":"Steiner S, Schmidt A, Zeller T, Tepe G, Thieme M, Maiwald L, Schr\u00f6der H, Euringer W, Ulrich M, Brechtel K, Brucks S, Blessing E, Schuster J, Langhoff R, Schellong S, Weiss N, Scheinert D (2020) COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J 41:2541\u20132552","journal-title":"Eur Heart J"},{"key":"2370_CR11","doi-asserted-by":"publisher","first-page":"e1445","DOI":"10.4244\/EIJ-D-21-00444","volume":"17","author":"F Liistro","year":"2022","unstructured":"Liistro F, Weinberg I, Almonacid Popma A, Shishehbor MH, Deckers S, Micari A (2022) Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the IN.PACT BTK randomised trial. EuroIntervention 17:e1445\u2013e1454","journal-title":"EuroIntervention"},{"key":"2370_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ejvs.2018.11.019","volume":"57","author":"A Boitet","year":"2019","unstructured":"Boitet A, Grassin-Delyle S, Louedec L, Dupont S, Lamy E, Coggia M, Michel JB, Coscas R (2019) An experimental study of paclitaxel embolisation during drug coated balloon angioplasty. Eur J Vasc Endovasc Surg 57:578\u2013586","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2370_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025677","volume":"12","author":"Y Soga","year":"2023","unstructured":"Soga Y, Takahara M, Iida O, Tomoi Y, Kawasaki D, Tanaka A, Yamauchi Y, Tobita K, Kozuki A, Fujihara M, Ando K, Investigators P (2023) Vessel patency and associated factors of drug-coated balloon for femoropopliteal lesion. J Am Heart Assoc 12:e025677","journal-title":"J Am Heart Assoc"},{"key":"2370_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00392-014-0775-2","volume":"104","author":"FX Kleber","year":"2015","unstructured":"Kleber FX, Schulz A, Waliszewski M, Hauschild T, B\u00f6hm M, Dietz U, Cremers B, Scheller B, Clever YP (2015) Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol 104:217\u2013225","journal-title":"Clin Res Cardiol"},{"key":"2370_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00392-013-0556-3","volume":"102","author":"B Scheller","year":"2013","unstructured":"Scheller B, Fischer D, Clever YP, Kleber FX, Speck U, B\u00f6hm M, Cremers B (2013) Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months. Clin Res Cardiol 102:469\u2013472","journal-title":"Clin Res Cardiol"},{"key":"2370_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12928-020-00672-4","volume":"36","author":"T Shimada","year":"2021","unstructured":"Shimada T, Habara S, Tanaka H, Kadota K (2021) Plaque volume reduction after drug-coated balloon angioplasty for superficial femoral artery lesion. Cardiovasc Interv Ther 36:263\u2013265","journal-title":"Cardiovasc Interv Ther"},{"key":"2370_CR17","doi-asserted-by":"crossref","first-page":"2050313X2090782","DOI":"10.1177\/2050313X20907825","volume":"8","author":"N Kobayashi","year":"2020","unstructured":"Kobayashi N, Hirano K, Yamawaki M, Araki M, Sakai T, Sakamoto Y, Mori S, Tsutsumi M, Nauchi M, Sahara N, Honda Y, Makino K, Shirai S, Mizusawa M, Sugizaki Y, Nakano T, Fukagawa T, Kishida T, Kozai Y, Setonaga Y, Goda S, Ito Y (2020) Sustained drug retention after paclitaxel-coated balloon angioplasty for superficial femoral artery disease: follow-up intravascular imaging. SAGE Open Med Case Rep. 8:2050313X20907825","journal-title":"SAGE Open Med Case Rep."},{"key":"2370_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00380-021-01912-0","volume":"37","author":"N Hayakawa","year":"2022","unstructured":"Hayakawa N, Kodera S, Arakawa M, Hirano S, Shakya S, Kanda J (2022) Clinical outcome of drug-coated balloon versus scaffold device in patients with superficial femoral artery chronic total occlusion. Heart Vessels 37:282\u2013290","journal-title":"Heart Vessels"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02370-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:04:53Z","timestamp":1718888693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02370-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2370"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02370-0","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}